Addex Therapeutics (ADXN) announced that following the previously announced termination of development of ADX71149 in epilepsy, its partner Janssen Pharmaceuticals (JNJ) has returned all development and commercialization rights to ADX71149 and the partnership between the two companies has been terminated.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue